Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180619 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
NCT03180619 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 124 participants.
The verdict
NCT03180619, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic impairment.
Interventions
- DRUG TAF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2020-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180619
The ClinicalTrials.gov registry entry for NCT03180619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAF is the first listed.
NCT03180619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03180619 about?
NCT03180619 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)". The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic impairment.
What is the current status of trial NCT03180619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2017-06-29. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03180619?
The interventions under investigation include: TAF (DRUG).
Who is sponsoring clinical trial NCT03180619?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.